NCT04550455View on ClinicalTrials.gov

A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 16, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

Cladribine Tablets

Cladribine tablets will be administered according the current package insert guidelines

Trial Locations (1)

12110

RECRUITING

Multiple Sclerosis Center of Northeastern New York, P.C., Latham

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

lead

Keith Edwards, M.D.

OTHER

NCT04550455 - A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets | Biotech Hunter | Biotech Hunter